glp-1 news october 1 2025 ISPOR 2025: Exploring reasons for discontinuation GLP-1 Weight-Loss Drug Demonstration Begins

The Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE) study demonstrated significant improvement in renal outcomes with canagliflozin in patients with T2DM and advanced macro-albuminuric kidney disease, as compared to placebo [63]

Thanks to the access to two parallels flow channels, the device allowed the quantification of the intestinal barrier function, as well as the measurement of the transepithelial absorption and transport

Analysts have previously expressed concerns that Omada isn't yet profitable (though the company narrowed its losses to about $3.2 million in the third quarter) and faces an increasingly competitive digital health market as it looks to compete with dozens of online GLP-1 prescribers

HPLC Purity Analysis High-performance liquid chromatography helps verify peptide purity and identify impurities